Avadel Pharma Files Proxy Statement
| Field | Detail |
|---|---|
| Company | Avadel Pharmaceuticals PLC |
| Form Type | DEFA14A |
| Filed Date | Dec 19, 2025 |
| Risk Level | low |
| Pages | 9 |
| Reading Time | 10 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, shareholder-meeting
TL;DR
Avadel Pharma filed its proxy statement on 12/19/25, get ready for shareholder votes.
AI Summary
Avadel Pharmaceuticals plc filed a Definitive Proxy Statement (DEFA14A) on December 19, 2025. The filing concerns the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. Greg Divis, the CEO, is mentioned in relation to the filing.
Why It Matters
This filing is a standard regulatory requirement for public companies, indicating that Avadel Pharmaceuticals is preparing for a shareholder meeting where important corporate decisions will be made.
Risk Assessment
Risk Level: low — A DEFA14A filing is a routine regulatory document and does not inherently indicate increased risk for the company.
Key Players & Entities
- AVADEL PHARMACEUTICALS PLC (company) — Registrant
- Greg Divis (person) — Chief Executive Officer
- 10 EARLSFORT TERRACE (location) — Company Business Address
- DUBLIN 2 (location) — Company Business Address City/Province
- 16640 CHESTERFIELD GROVE ROAD (location) — Company Mail Address
- CHESTERFIELD (location) — Company Mail Address City
- MO (location) — Company Mail Address State
- FLAMEL TECHNOLOGIES SA (company) — Former Company Name
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, allowing them to vote on corporate matters.
When was this DEFA14A filed by Avadel Pharmaceuticals plc?
This DEFA14A was filed on December 19, 2025.
Who is identified in the filing in a leadership role?
Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals, is mentioned in the filing.
What is Avadel Pharmaceuticals plc's primary industry classification?
Avadel Pharmaceuticals plc is classified under 'PHARMACEUTICAL PREPARATIONS' with SIC code [2834].
Does the filing indicate a fee was paid?
The filing indicates that no fee was required for this filing.
Filing Stats: 2,583 words · 10 min read · ~9 pages · Grade level 15.7 · Accepted 2025-12-19 16:15:20
Filing Documents
- tm2534012d1_defa14a.htm (DEFA14A) — 36KB
- 0001104659-25-123152.txt ( ) — 37KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This communication contains forward-looking by words such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “seek,” “continue,” “could,” “can,” “may,” “will,” “likely,” “depend,” “should,” “would,” “plan,” “predict,” “target,” and similar expressions, and may include references to assumptions and relate to Avadel’s and Alkermes’ future prospects, developments and business strategies, and the Acquisition. Such forward-looking statements include, but are not limited to, statements relating to the Acquisition involving Alkermes and Avadel, current expectations and estimates about the Acquisition and the anticipated benefits of the Acquisition, including the parties’ ability to satisfy the conditions to the consummation of the Acquisition and the other conditions set forth in the Transaction Agreement. Avadel’s and Alkermes’ expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: (i) the ability of the parties to consummate the Acquisition in a timely manner or at all; (ii) the satisfaction (or waiver) of conditions to the consummation of the Acquisition, including with respect to the approval of Avadel shareholders; (iii) the possibility that more competing offers for Avadel may be made; (iv) potential delays in consummating the Acquisition; (v) the ability of Avadel to timely and successfully achiev